TrialHuman vaccines & immunotherapeutics2014

Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Michael L Forbes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.